Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) EVP Neena M. Patil sold 3,800 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the sale, the executive vice president now owns 33,318 shares of the company's stock, valued at $4,826,778.66. This trade represents a 10.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Jazz Pharmaceuticals Price Performance
Jazz Pharmaceuticals stock opened at $140.22 on Tuesday. The company's 50 day simple moving average is $127.01 and its 200-day simple moving average is $119.37. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06. The company has a market capitalization of $8.52 billion, a price-to-earnings ratio of 19.75, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56.
Wall Street Analyst Weigh In
A number of research firms have commented on JAZZ. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their price objective for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. HC Wainwright reiterated a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. TD Cowen lowered their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a research note on Thursday, November 7th. Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Finally, Barclays reissued an "overweight" rating and set a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $182.47.
View Our Latest Report on JAZZ
Institutional Trading of Jazz Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. IFP Advisors Inc purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth $25,000. Quadrant Capital Group LLC lifted its stake in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 101 shares in the last quarter. Elequin Capital LP lifted its stake in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 183 shares in the last quarter. CoreFirst Bank & Trust purchased a new position in Jazz Pharmaceuticals during the 4th quarter valued at about $28,000. Finally, Allianz SE acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at about $29,000. Hedge funds and other institutional investors own 89.14% of the company's stock.
About Jazz Pharmaceuticals
(
Get Free Report)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
